Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide

Breast cancer (BC) is the most commonly diagnosed cancer in women and one of the most common causes of cancer-related deaths. Despite intense research efforts, BC treatment still remains challenging. Improved drug development strategies are needed for impactful benefit to patients. Current preclinic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marco Cavaco, Patrícia Fraga, Javier Valle, David Andreu, Miguel A. R. B. Castanho, Vera Neves
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/f01c0e8ba06d4b4390251fcc52ee3d03
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f01c0e8ba06d4b4390251fcc52ee3d03
record_format dspace
spelling oai:doaj.org-article:f01c0e8ba06d4b4390251fcc52ee3d032021-11-25T18:41:15ZDevelopment of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide10.3390/pharmaceutics131118631999-4923https://doaj.org/article/f01c0e8ba06d4b4390251fcc52ee3d032021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1863https://doaj.org/toc/1999-4923Breast cancer (BC) is the most commonly diagnosed cancer in women and one of the most common causes of cancer-related deaths. Despite intense research efforts, BC treatment still remains challenging. Improved drug development strategies are needed for impactful benefit to patients. Current preclinical studies rely mostly on cell-based screenings, using two-dimensional (2D) cell monolayers that do not mimic in vivo tumors properly. Herein, we explored the development and characterization of three-dimensional (3D) models, named spheroids, of the most aggressive BC subtypes (triple-negative breast cancer-TNBC; and human-epidermal growth receptor-2-HER2+), using the liquid overlay technique with several selected cell lines. In these cell line-derived spheroids, we studied cell density, proliferation, ultrastructure, apoptosis, reactive oxygen species (ROS) production, and cell permeabilization (live/dead). The results showed a formation of compact and homogeneous spheroids on day 7 after seeding 2000 cells/well for MDA-MB-231 and 5000 cells/well for BT-20 and BT-474. Next, we compared the efficacy of a model anticancer peptide (ACP) in cell monolayers and spheroids. Overall, the results demonstrated spheroids to be less sensitive to treatment than cell monolayers, revealing the need for more robust models in drug development.Marco CavacoPatrícia FragaJavier ValleDavid AndreuMiguel A. R. B. CastanhoVera NevesMDPI AGarticle3D cell cultureanticancer peptidesbreast cancercell monolayerspreclinical studiesspheroidsPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1863, p 1863 (2021)
institution DOAJ
collection DOAJ
language EN
topic 3D cell culture
anticancer peptides
breast cancer
cell monolayers
preclinical studies
spheroids
Pharmacy and materia medica
RS1-441
spellingShingle 3D cell culture
anticancer peptides
breast cancer
cell monolayers
preclinical studies
spheroids
Pharmacy and materia medica
RS1-441
Marco Cavaco
Patrícia Fraga
Javier Valle
David Andreu
Miguel A. R. B. Castanho
Vera Neves
Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
description Breast cancer (BC) is the most commonly diagnosed cancer in women and one of the most common causes of cancer-related deaths. Despite intense research efforts, BC treatment still remains challenging. Improved drug development strategies are needed for impactful benefit to patients. Current preclinical studies rely mostly on cell-based screenings, using two-dimensional (2D) cell monolayers that do not mimic in vivo tumors properly. Herein, we explored the development and characterization of three-dimensional (3D) models, named spheroids, of the most aggressive BC subtypes (triple-negative breast cancer-TNBC; and human-epidermal growth receptor-2-HER2+), using the liquid overlay technique with several selected cell lines. In these cell line-derived spheroids, we studied cell density, proliferation, ultrastructure, apoptosis, reactive oxygen species (ROS) production, and cell permeabilization (live/dead). The results showed a formation of compact and homogeneous spheroids on day 7 after seeding 2000 cells/well for MDA-MB-231 and 5000 cells/well for BT-20 and BT-474. Next, we compared the efficacy of a model anticancer peptide (ACP) in cell monolayers and spheroids. Overall, the results demonstrated spheroids to be less sensitive to treatment than cell monolayers, revealing the need for more robust models in drug development.
format article
author Marco Cavaco
Patrícia Fraga
Javier Valle
David Andreu
Miguel A. R. B. Castanho
Vera Neves
author_facet Marco Cavaco
Patrícia Fraga
Javier Valle
David Andreu
Miguel A. R. B. Castanho
Vera Neves
author_sort Marco Cavaco
title Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
title_short Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
title_full Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
title_fullStr Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
title_full_unstemmed Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
title_sort development of breast cancer spheroids to evaluate cytotoxic response to an anticancer peptide
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/f01c0e8ba06d4b4390251fcc52ee3d03
work_keys_str_mv AT marcocavaco developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
AT patriciafraga developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
AT javiervalle developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
AT davidandreu developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
AT miguelarbcastanho developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
AT veraneves developmentofbreastcancerspheroidstoevaluatecytotoxicresponsetoananticancerpeptide
_version_ 1718410808345493504